Friday, October 2, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· March 11, 2026

Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026

View original at globenewswire.com
Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • TPST-2003 represents one of the largest datasets evaluating a CD19/BCMA dual-targeting CAR-T therapy

    60% confidence

  • The parallel-structure dual-targeting CAR architecture of TPST-2003 is truly innovative

    60% confidence

  • Tempest plans to present the results of the REDEEM-1 trial and updated results from the IIT at a scientific meeting later this year

    60% confidence

  • A total of 36 patients with rrMM had received one infusion of TPST-2003 as of January 31, 2026, including 24 patients in IIT and 12 patients in REDEEM-1

    60% confidence

  • All activities other than long-term stability testing planned to be complete in Q3 2026

    60% confidence

  • The potential to treat patients with extramedullary disease (EMD) and patients who have previously received a BCMA-targeting CAR-T is particularly exciting

    60% confidence

  • The recent positive results from the ongoing REDEEM-1 trial position TPST-2003 as a potential class-leading therapy for rrMM

    60% confidence

  • The parallel-structure dual-targeting CAR architecture of TPST-2003 is truly innovative

    60% confidence

  • TPST-2003 has the potential to treat patients with extramedullary disease (EMD) and patients who have previously received a BCMA-targeting CAR-T

    60% confidence

  • All activities other than long-term stability testing planned to be complete in Q3 2026 to support potential IND filing in Q4 2026

    60% confidence

  • This represents one of the largest datasets evaluating a CD19/BCMA dual-targeting CAR-T therapy

    60% confidence

  • The recent positive results from the ongoing REDEEM-1 trial position TPST-2003 as a potential class-leading therapy for relapsed/refractory multiple myeloma

    60% confidence

  • Tempest plans to present the results of the REDEEM-1 trial and updated results from the IIT at a scientific meeting later this year

    60% confidence

  • Total of 36 patients with relapsed/refractory multiple myeloma had received one infusion of TPST-2003 as of January 31, 2026 data cutoff, including 24 patients in prior Phase 1/2 investigator-initiated trial and 12 patients in ongoing REDEEM-1 trial

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com